Chloride/Phosphate Ratio in Primary Hyperparathyroidism

Boughey, J. C.; Ewart, C. J.; Yost, M. J.; Nottingham, J. M.; Brown, J. J.
January 2004
American Surgeon;Jan2004, Vol. 70 Issue 1, p25
Academic Journal
The chloride/phosphate (ChPO4) ratio is known to help distinguish between the hypercalcemia of primary hyperparathyroidism (HPT) and hypercalcemia from other causes. The ChPO4 ratio of 106 patients with surgically proven primary HPT was compared with that of 126 normocalcemic healthy outpatients to examine its usefulness as a confirmatory test for primary HPT. The ChPO4 ratio was significantly higher in patients with HPT (42.5 ± 7.0) compared with healthy controls (28.7 ± 4.6). Patients with HPT and mild renal insufficiency (serum creatinine, 1.5-2.4 mg/dL) also showed a significant increase in the ChPO4 ratio (37.3 ± 6.6) as did those with HPT with borderline elevations in serum calcium (calcium <11; ChPO4, 40.3 ± 5.6). A ChPO4 ratio ≥ 33 is a reliable diagnostic test for primary HPT when compared with a normal population. The CI:PO4 ratio is also of value in the evaluation of the patient with suspected HPT and borderline calcium elevation and those with mild renal impairment. These data suggest that an inexpensive CI:PO4 ratio might replace serum parathormone assay as a confirmatory test in the evaluation of suspected primary HPT, especially for those patients in whom a localizing study (sestamibi scan) is obtained before neck exploration.


Related Articles

  • Primary Hyperparathyroidism: Problems for Clinician and Chemist. E.J.H. // Annals of Internal Medicine;Dec62, Vol. 57 Issue 6, p1052 

    Editorial. Focuses on primary hyperparathyroidism. Syndromes associated with hyperparathyroidism; Detection of hypercalcemia; Relative value of the tests of phosphate handling by the kidney; Elevations of the serum calcium level in patients with hyperparathyroidism.

  • Recent developments in the management of secondary hyperparathyroidism. Goodman, William G. // Kidney International;Mar2001, Vol. 59 Issue 3, p1187 

    Highlights the developments in the management of secondary hyperparathyroidism. Attribution of hyperphosphatemia with the compliance with the dietary guidelines; Prevention of phosphate retention and hyperphosphatemia; Maintenance of normal concentration of calcium in serum.

  • DIALYSIS - TRANSPLANTATION Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Qunibi, Wajeh Y.; Hootkins, Robert E.; McDowell, Laveta L.; Meyer, Micah S.; Simon, Matthias; Garza, Rodolfo O.; Pelham, Russell W.; Cleveland, Mark V. B.; Muenz, Larry R.; He, David Y.; Nolan, Charles R. // Kidney International;May2004, Vol. 65 Issue 5, p1914 

    Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Background. Hyperphosphatemia underlies development of hyperparathyroidism, osteodystrophy, extraosseous calcification, and is associated with increased mortality in hemodialysis...

  • Primary Hyperparathyroidism. Marcocci, Claudio; Cetani, Filomena // New England Journal of Medicine;12/22/2011, Vol. 365 Issue 25, p2389 

    The article provides information on primary hyperparathyroidism, which is the common cause of hypercalcemia and should be considered in people with elevated serum calcium levels. It says that long-term lithium therapy and head and neck irradiation in childhood are associated with a greater...

  • Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects. Duntas, Leonidas H.; Stathatos, Nikolaos // Endocrine (1355008X);Jun2011, Vol. 39 Issue 3, p199 

    Primary hyperparathyroidism (pHPT), which most frequently occurs asymptomatically, is a common endocrine disease associated with increased morbidity and mortality. The newly introduced management guidelines as well as the recent availability of the first calcimimetic offer a highly promising...

  • Warfarin-induced calciphylaxis: a case report and review of literature. Saifan, Chadi; Saad, Marc; El-Charabaty, Elie; El-Sayegh, Suzanne // International Journal of General Medicine;2013, Vol. 6, p665 

    Calciphylaxis is a challenging complication of end-stage renal disease, with an unknown underlying mechanism. Several risk factors have been identified, such as hyperphosphatemia, hypercalcemia, hyperparathyroidism, low serum albumin levels, and history of warfarin therapy. This article presents...

  • Precipitous fall in serum calcium, hypotension, and acute renal failure after intravenous phosphate therapy for hypercalcemia. Report of two cases. Shackney, Stanley; Hasson, Jack; Shackney, S; Hasson, J // Annals of Internal Medicine;May67, Vol. 66 Issue 5, p906 

    Focuses on the precipitous decrease in serum calcium associated with hypotension and acute renal failure after therapy with intravenously administered phosphate buffer in several hypercalcemic patients. Details of the case of patients with hypercalcemia; Clinical features of the responses of...

  • Cortisone Responsive Hypercalcemia in Proved Hyperparathyroidism. Gwinup, Grant; Sayle, Bettye // Annals of Internal Medicine;Dec61, Vol. 55 Issue 6, p1001 

    Reports cases of cortisone responsive hypercalcemia in proved hyperparathyroidism. Differential diagnosis; Hypercalcemia of sarcoidosis; Relationship between hypercalcemia and neoplasm.

  • Humoral hypercalcemia of malignancy. Burtis, William J.; Wu, Terence L.; Insogna, Karl L.; Stewart, Andrew F.; Burtis, W J; Wu, T L; Insogna, K L; Stewart, A F // Annals of Internal Medicine;Mar88, Vol. 108 Issue 3, p454 

    Editorial. Focuses on humoral hypercalcemia of malignancy. Nature of hypercalcemia; Syndromes of humoral hypercalcemia of malignancy; Difference between patients with humoral hypercalcemia of malignancy and patients with primary hyperparathyroidism.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics